m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03935)
Name
MK-4621
Status
Phase 1
TTD Drug ID
DFO5W3
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Retinoic acid-inducible gene-1 (RIG-1)
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Retinoic acid-inducible gene-1 (RIG-1) is a therapeutic target for MK-4621. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of MK-4621 through regulating the expression of Retinoic acid-inducible gene-1 (RIG-1). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Retinoic acid-inducible gene-1 (RIG-1) is a therapeutic target for MK-4621. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MK-4621 through regulating the expression of Retinoic acid-inducible gene-1 (RIG-1). [2], [3]
References
Ref 1 N (6)-Methyladenosine modification of hepatitis B and C viral RNAs attenuates host innate immunity via RIG-I signaling. J Biol Chem. 2020 Sep 11;295(37):13123-13133. doi: 10.1074/jbc.RA120.014260. Epub 2020 Jul 27.
Ref 2 Clinical pipeline report, company report or official report of CureVac.
Ref 3 METTL3 regulates viral m6A RNA modification and host cell innate immune responses during SARS-CoV-2 infection. Cell Rep. 2021 May 11;35(6):109091. doi: 10.1016/j.celrep.2021.109091. Epub 2021 May 3.